Pfizer (PFE.N), BioNTech (22UAy.DE) and biotech firm Promosome told a federal judge in San Diego, California that they have agreed to end Promosome’s lawsuit accusing the COVID-19 vaccine makers of infringing a patent related to messenger RNA technology.
The companies said in a court filing on Wednesday that Promosome would dismiss its case with prejudice, which means it cannot be refiled, and that Promosome had agreed not to bring future claims over the patent against Pfizer and its partner BioNTech. No financial terms were disclosed.
Representatives for Promosome and Pfizer did not immediately respond to requests for comment on Thursday. A representative for BioNTech’s attorneys declined to comment on the filing.
The agreement comes weeks after Promosome abandoned a related lawsuit against COVID-19 vaccine maker Moderna (MRNA.O).
San Diego and New York-based Promosome was formed to commercialize technology developed by biochemistry researchers at the Scripps Research Institute in La Jolla, California. Promosome sued Pfizer, BioNTech and Moderna in June, accusing the companies of copying its technology for making doses of mRNA small enough to use safely and effectively in the vaccines.
The lawsuits said that Promosome discussed its technology with representatives from Moderna and BioNTech between 2013 and 2016.
Promosome had asked the court for a share of royalties from the shots. Pfizer earned $37.8 billion last year from sales of its COVID-19 vaccine Comirnaty, while Moderna made $18.4 billion from its vaccine Spikevax.
Pfizer and BioNTech denied the allegations and claimed Promosome had withheld information from the U.S. Patent Office when applying for the patent that would have rendered it invalid.
The Promosome lawsuits were among several U.S. patent cases brought by biotech companies over the alleged misuse of their technology in the groundbreaking shots. Moderna filed a patent lawsuit against Pfizer and BioNTech last year that is still ongoing.
Check out our AAV CDMO service to expedite your gene therapy research
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Beacon raises $170M to take on J&J in ocular gene therapy
Transatlantic biotech Beacon Therapeutics has raised $170 million to potentially bring a rare ophthalmology gene therapy to market in a competition with Johnson & Johnson. J&J is ahead of Beacon, having fully enrolled its late-stage test of botaretigene...
GSK Pays $430M Upfront for CureVac’s COVID-19, Flu mRNA Vaccines
GSK on Wednesday announced it is restructuring an existing collaboration agreement with German biotech CureVac, focusing on their investigational mRNA vaccines for influenza and COVID-19 while withdrawing from other infectious disease projects. Under the amended...
J&J, Legend’s Phase III Win Cements Carvykti as Earlier-Line Multiple Myeloma Treatment
Johnson & Johnson and Legend Biotech on Tuesday released interim results from the Phase III CARTITUDE-4 study, touting significant survival improvement in multiple myeloma patients after treatment with their CAR-T therapy Carvykti (ciltacabtagene autoleucel). The...
FDA Approves Lilly’s Donanemab While Rejections Highlight Manufacturing Issues
The biggest news of the week was the FDA approval of Eli Lilly’s Kisunla (donanemab) on Tuesday. While not unexpected, it was one of the year’s most highly anticipated decisions. And last week saw another big approval from the FDA—that of Verona’s novel COPD drug. But...
Related Services
Plasmids GMP Services
Multiple scales & grade of solutions of various kind of plasmids suitable for multiple treatments in a fast and cost effective way.
READ MORE
AAV GMP Services
Ranging from small-scale AAV production, to large-scale AAV cGMP manufacturing for animal studies.
READ MORE
Technology Platforms
PackGene’s proprietary π-Alpha™ 293 AAV High-yield Platform increases AAV production by 3 to 8 times that of traditional platforms.
READ MORE
